Abstract 4426: Are there synergistic antiproliferative effects of paclitaxel and curcumin on osseus metastasis of renal cell carcinoma

Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Aim: Human renal cell carcinomas (RCCs) are highly resistant to conventional chemotherapy. Recently, paclitaxel has been shown to inhibit growth of RCCs in vitro. Therefore, we analyzed the chemotherapeutic potential of paclitaxel on our established cell line N109, derived from an osseous metastasis of a human RCC. In addition, we examined the role of the phytochemical curcumin on the growth inhibition which is known to act as a modulator of the Multidrug Resistance Phenotype. Methods: MTT assay, immunfluorescence microscopy and flow cytometry. Results: 1. Significant dose-dependent growth inhibition and paclitaxel-induced morphological alterations were observed in the cell line N109. 2. No significant dose-dependent growth inhibition was observed after exposure to curcumin alone. 3. A synergistic effect of growth inhibition was detected after treatment with both, paclitaxel and curcumin. 4. The cell line N109 shows a pronounced P-glycoprotein expression. 5. After exposure to paclitaxel or curcumin no remarkable modulation of the P-glycoprotein expression level was observed. Conclusion: This study demonstrates that paclitaxel can effectively inhibit the growth of an osseous metastasis of human renal cell carcinoma in vitro whereas a pronouced synergistic inhibition effect in combination with the phytochemical curcumin became evident. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4426.